Antioxidant vitamins and prevention of cardiovascular disease: Epidemiological and clinical trial data
Antioxidant vitamins and prevention of cardiovascular disease: Epidemiological and clinical trial data
复制标题
DOI：
10.1007/s11745-001-0683-y
复制
发表时间：
2001-01-01
期刊：
影响因子：
1.9
通讯作者：
Valagussa, F
中科院分区：
文献类型：
--
作者：
Marchioli, R;Schweiger, C;Valagussa, F
天然存在的抗氧化剂如维生素E、β-胡萝卜素和维生素C可以抑制低密度脂蛋白的氧化修饰。这种作用可以积极影响动脉粥样硬化过程，因此，冠心病的进展。大量的实验研究为抗氧化剂的作用机制提供了可靠的生物学依据，而流行病学研究则有力地支持了“抗氧化剂假说”。“然而，迄今为止，β-胡萝卜素补充剂的临床试验令人失望，应该劝阻将其用作癌症和冠心病的预防干预措施。只有很少的临床试验数据可用于维生素C。关于维生素E，α-生育酚、β-胡萝卜素预防癌症研究（补充低剂量维生素E（50 mg/d））和剑桥心脏抗氧化剂研究（400-800 mg/d）获得了不一致的结果。GISSI-Eschizione（300 mg/d）和HOPE（400 mg/d）试验的结果表明，维生素E对心血管事件风险没有相关的临床影响。目前正在进行的几项大规模临床试验将有助于阐明维生素E与其他抗氧化剂在预防动脉粥样硬化性冠状动脉疾病中的作用。
Naturally occurring antioxidants such as vitamin E, P-carotene, and vitamin C can inhibit the oxidative modification of low density lipoproteins. This action could positively influence the atherosclerotic process and, as a consequence, the progression of coronary heart disease. A wealth of experimental studies provide a sound biological rationale for the mechanisms of action of antioxidants, whereas epidemiologic studies strongly sustain the "antioxidant hypothesis." To date, however, clinical trials with P-carotene supplements have been disappointing, and their use as a preventive intervention for cancer and coronary heart disease should be discouraged. Only scanty data from clinical trials are available for vitamin C. As to vitamin E, discrepant results have been obtained by the Alpha-Tocopherol, Beta Carotene Cancer Prevention Study with a low-dose vitamin E supplementation (50 mg/d) and the Cambridge Heart Antioxidant Study (400-800 mg/d). The results of the GISSI-Prevenzione (300 mg/d) and HOPE (400 mg/d) trials suggest the absence of relevant clinical effects of vitamin E on the risk of cardiovascular events. Currently ongoing are several large-scale clinical trials that will help in clarifying the role of vitamin E in association with other antioxidants in the prevention of atherosclerotic coronary disease.